CMS Examines Coverage Options for HIV PrEP Preventative Care
A new analysis has been launched by the US Centers for Medicare and Medicaid Services (CMS) to evaluate the nationwide coverage of HIV preexposure prophylaxis (PrEP), a group of antiretroviral drugs that prevent HIV infections and transmission when taken appropriately. The drugs, which hover at around $2300 a year, fall under Medicare coverage for some states but not all.
HIV/AIDS Patient Advocacy Organization Incensed by Gilead’s 340B Descovy Price Hikes
Gilead Sciences’ refusal to provide Medicare 340B discounts for HIV drugs has drawn significant ire from HIV/AIDS patient advocacy organizations. The AIDS Healthcare Foundation (AHF) said that the pharma giant has spiked the price of its HIV drug Descovy for providers and pharmacies that deliver care to underserved communities. Gilead claims its HIV drugs do not qualify for its Contract Pharmacy Integrity Initiative.
Gilead Science’s Long-Acting HIV Drug Secures Win With EU Approval
Gilead Science has received approval from the European Commission for its HIV drug lenacapavir. The medication is used to treat multi-drug resistant HIV and is injected once every six months. This approval marks a win for Gilead, as the drug was placed on a temporary clinical by the FDA over the risk of contamination from glass shards.
A Bridge Too Far: The High Cost of Gilead’s HIV Prevention Pill
A new analysis by U.S. government researchers found that the high cost of the world’s only HIV prevention pill may [...]
